{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:07:05Z","timestamp":1768734425607,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008782","name":"University of Hawai&apos;i","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013758","name":"Department of Psychiatry, Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jad.2019.10.050","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T22:04:07Z","timestamp":1572645847000},"page":"40-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series"],"prefix":"10.1016","volume":"262","author":[{"given":"Brett Y.","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Agapoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Roller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Goebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2019.10.050_bib0001","first-page":"579","article-title":"Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial","volume":"26","author":"Amsterdam","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0002","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/JCP.0000000000000894","article-title":"Maintenance ketamine therapy for treatment-resistant depression","volume":"38","author":"Archer","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.10.050_bib0003","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0004","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/17425247.2016.1140145","article-title":"Critical appraisal of selegiline transdermal system for major depressive disorder","volume":"13","author":"Cristancho","year":"2016","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.jad.2019.10.050_bib0005","first-page":"25","article-title":"A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression","volume":"10","author":"Culpepper","year":"2008","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0006","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/1520-6394(2000)12:3<130::AID-DA4>3.0.CO;2-C","article-title":"Side effects of electroconvulsive therapy","volume":"12","author":"Datto","year":"2000","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2019.10.050_bib0007","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0008","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","author":"Fava","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0009","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4088\/JCP.v67n0905","article-title":"Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial","volume":"67","author":"Feiger","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","article-title":"Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder","volume":"215","author":"Ghasemi","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2019.10.050_bib0011","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.10.050_bib0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0013","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.wnf.0000171248.89726.2f","article-title":"Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report","volume":"28","author":"Higuchi","year":"2005","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2019.10.050_bib0014","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0015","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0016","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.jcp.0000270085.15253.15","article-title":"Treatment-resistant depression: response to low-dose transdermal but not oral selegiline","volume":"27","author":"Morgan","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.10.050_bib0017","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0018","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jad.2013.11.014","article-title":"A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action","volume":"156","author":"Naughton","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.10.050_bib0019","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/03007995.2016.1277201","article-title":"Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis","volume":"33","author":"Papadimitropoulou","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2019.10.050_bib0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/070674371005500303","article-title":"The sequenced treatment alternatives to relieve depression (STAR* D) trial: a review","volume":"55","author":"Sinyor","year":"2010","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0021","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archpsyc.1994.03950080019003","article-title":"High-dose selegiline in treatment-resistant older depressive patients","volume":"51","author":"Sunderland","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.050_bib0022","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2017","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271931910X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271931910X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:29:38Z","timestamp":1759022978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503271931910X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":22,"alternative-id":["S016503271931910X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.10.050","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.10.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}